Publications: Scientific Presentations

On June 4, 2009, Dr. Paolo Lecchi, Director of Correlogic’s Mass Spectrometry Laboratory, presented Correlogic’s poster, “Assessing the Reproducibility of Direct Infusion Mass Spectrometric Analyses using Thermometer Ions” at the American Society for Mass Spectrometry’s annual conference. This poster describes a new strategy for mapping, optimizing and monitoring the electrospray ion source on a mass spectrometer.

On June 3, 2008, at the American Society for Mass Spectrometry’s conference on Mass Spectrometry and Allied Topics, Dr. Paolo Lecchi, Director of Correlogic’s Mass Spectrometry Laboratory, presented Correlogic’s poster, Defining Instrument Performance and Assessing the Reproducibility of Mass Spectrometric Analyses of Complex Samples. The poster details Correlogic’s patent-pending strategy for monitoring and optimizing the performance of mass spectrometers for use in pattern analysis. In order for mass spectrometry to generate reliable classifications for serum samples, factors such as variability between instruments and across locations, and drift over time must be controlled. Dr. Lecchi and Dr. John Peltier, Correlogic’s Senior Director of Spectrometry, along with a team of Correlogic scientists, devised a novel approach that utilizes a series of compounds to serve as an "artificial standard pattern" (ASP) to monitor and address mass spectrometric reproducibility. The study demonstrated that subtle drift in the ASP across time and instruments could be monitored — supporting the practicality of this method for the evaluation and standardization of MS-based profiling experiments.

Our spore research with Charles Stark Draper Laboratory and Tufts University School of Medicine was presented as a poster “Detection and Differentiation of Bacillus Spores Using Pyrolysis: Differential Mobility Spectrometry and Genetic Algorithms” at the Pittcon Homeland Security and Forensics session, March 16, 2006.

On May 15, 2005, at the annual meeting of the American Society of Clinical Oncologists (ASCO) in Orlando Florida, Correlogic made its first major presentation of the results of our breast cancer research with the Clinical Breast Care Project of Walter Reed Army Medical Center.  Our poster, “A Serum Pattern Predictive of Breast Cancer” outlined progress in developing a diagnostic blood test for breast cancer.  Using sera from 371 women with normal or benign breast conditions and sera from 234 women with invasive cancer, we generated a model that demonstrated 80.5 percent sensitivity and 94.4 percent specificity on a blinded set of 54 normal benign and 41 invasive cancer sera.  Our collaboration with Walter Reed Army Medical Center is ongoing.

On March 16, 2005, Correlogic’s Chief Science Officer, Ben Hitt, spoke before the Third Annual IBC Biomarker Pipeline Conference meeting in Boston.  Dr. Hitt discussed the "Use of Seromic^™ Patterns in Early Detection of Ovarian Cancer."

On September 28, 2004, Dr. Timothy Coleman, Vice President of Research and Development for Correlogic, presented “A New Paradigm: Pattern Recognition and Clinical Proteomics” at BioJapan 2004. Dr. Coleman discussed the results of Correlogic’s ongoing research on pattern recognition in disease detection in the Pharmacoproteome symposium, chaired by Dr. Yoshiji Fujita, Professor of Molecular Biology and Biotechnology, University of Sheffield. BioJapan is held quadrennially and brings together leading research organizations and institutions from around the world.

Correlogic's poster presentation "High-Throughput Multidimensional Mass Spectrometry Analysis for the Detection of Early Stage Epithelial Ovarian Cancer: A Serum Test for Ovarian Cancer." appeared at the Society of Gynecologic Investigation conference in Houston, TX on March 25, 2004.  The poster presented results that were 97 percent sensitive and 94 percent specific in validation.

On August 6, 2003, Ben Hitt presented “Changing the Prognosis for Ovarian Center: New Test for Early Detection”at the Strategic Research Institute’s Disease Management Conference in Boston, MA.

Correlogic Systems and Advion BioSciences presented further methods development in a poster entitled “Application of Chip-Based, Automated Nanoelectrospray Mass Spectrometry for Proteomic Pattern Recognition” at the CHI Protein Biomarkers conference in Philadelphia, PA in August 2003. Utilizing an optimized samples preparation process, we obtained an improved model for ovarian cancer.

At the July 2003 conference of the American Association for Cancer Research, the NCI presented “Multiple High Resolution Serum Proteomic Patterns for Ovarian Cancer Detection,” which detailed further improved results achieved by the Correlogic/NCI/FDA team.
Read an excerpt of the NIH/NCI release

On June 12, 2003, Correlogic Systems and Advion BioSciences presented a poster entitled “Development of a Proteome Marker Model for Ovarian Cancer Using Direct Analysis of Diluted Serum by Automated Nanoelectrospray TOF-MS” at the 51st meeting of the American Society for Mass Spectrometry in Montreal, Canada. The poster described our study of the use of Advion’s Nano Electrspray Ionization (nESI) in concert with Correlogic’s proprietary technology to model disease states. This represents the first published results from the co-development agreement announced on May 14, 2003.

On May 28, 2003, Ben Hitt presented “Application of Pattern Discovery Technology to Biomarker Identification” at the Molecular Diagnostic and Targeted Therapeutics conference sponsored by IBC in Boston, MA.